Multiple facets in the control of acromegaly
Visualizar/ Abrir
Data
2013-11-23Autor(es)
Vilar, LucioValenzuela, Alex
Ribeiro-Oliveira Jr, Antônio
Gomez Giraldo, Claudia Milena
Pantoja, Doly
Bronstein, Marcello D
Autor(es) Corporativo(s)
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Endocrinología
Tipo
Artículo de revista
ISSN
1386-341X / 1573-7403 (Electrónico)
COAR
Artículo de revistaCompartilhe este registro
Citación
Metadata
Mostrar registro completo
Documentos PDF
Abstract
Aims The current article provides a brief overview of the criteria for defining disease control in acromegaly.
Methods This was a retrospective, narrative review of previously published evidence chosen at the author’s discretion along with an illustrative case study from Latin America.
Findings and ConclusionsIn the strictest sense, “cure” in acromegaly is defined as complete restoration of normal pulsatile growth hormone secretion, although this is rarely achieved. Rather than “cure”, as such, it is more appropriate to refer to disease control and remission, which is defined mainly in terms of specific biochemical targets (for growth hormone and insulin-like growth factor-1) that predict or correlate with symptoms, comorbidities and mortality. However, optimal management of acromegaly goes beyond biochemical control to include control of tumour growth (which may be independent of biochemical control) and comprehensive management of the symptoms and comorbidities typically associated with the disease, as these may not be adequately managed with acromegaly-specific therapy alone.
Keywords
AcromegalyPituitary
Latin America
GH
IGF-1
Tumor shrinkage
Comorbidities
Somatostatin analogs
Link para o recurso
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906559/Fonte
Pituitary; Volumen 17 Número 1 , Páginas 11 - 17 (2013)
Google Analytics Statistics
Collections
- Artículos [56]